Welcome to our dedicated page for Cardiol Therapeu SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Cardiol Therapeutics Inc. (CRDL) provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Cardiol files reports on Form 6-K under the Securities Exchange Act of 1934, which transmit key documents such as financial statements, management’s discussion and analysis, and material news releases related to its operations as a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease.
Among the filings, investors can find condensed interim consolidated financial statements and accompanying management’s discussion and analysis for specified periods, as referenced in Form 6-K submissions. These documents outline operating results, research and development spending, and other financial information relevant to Cardiol’s clinical programs, including the MAVERIC Program in recurrent pericarditis and the ARCHER trial in acute myocarditis.
Form 6-K filings also incorporate news releases that describe important corporate events. Examples include announcements of private placement financings that support the pivotal Phase III MAVERIC trial and the development of CRD-38, updates on clinical trial milestones such as database lock and topline results from ARCHER, and disclosures about intellectual property developments like the U.S. patent allowance for cannabidiol compositions in heart conditions. Additional exhibits may include reports of exempt distributions and material change reports filed in connection with financings or other significant events.
On Stock Titan, these SEC filings are organized chronologically and can be paired with AI-powered summaries that explain the main points of each document in clear language. Users can quickly scan Form 6-K submissions, understand which exhibits are attached—such as financial statements, certifications of interim filings, or specific news releases—and identify items relevant to Cardiol’s clinical-stage cardiovascular pipeline, regulatory designations, and capital-raising activities.
Cardiol Therapeutics Inc. filed a Form F-10 base shelf registration to offer up to US $150,000,000 of securities under the MJDS. The shelf covers Common Shares, Debt Securities, Warrants, Subscription Receipts, and Units, to be sold from time to time during the 25-month period the prospectus remains effective, with specific terms to be set in prospectus supplements.
Amendment No. 1 adds that one or more selling securityholders may conduct secondary offerings by prospectus supplement, and the aggregate amount available for the company’s sales will be reduced by the aggregate amount of such secondary offerings. Cardiol’s Common Shares trade on the TSX and Nasdaq under “CRDL”.
Cardiol Therapeutics Inc. filed a Form 6-K as a foreign private issuer that reports under Form 40-F. The filing mainly furnishes a news release dated November 5, 2025, announcing that results from its Phase II ARCHER clinical trial will be presented at the European Society of Cardiology’s Scientific Meeting on Myocardial & Pericardial Diseases.
Cardiol Therapeutics (CRDL) filed a Form 6-K furnishing a news release as Exhibit 99.1. The exhibit, dated October 21, 2025, states the company completed a US$11.4 million financing and extended its cash runway into Q3 2027.
This is an informational submission under the Exchange Act for foreign private issuers and directs readers to the attached news release for details.
Cardiol Therapeutics (CRDL) furnished a Form 6‑K that includes a news release titled “Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027.” The filing signals that the company has secured US$11 million in financing, which the company states extends its cash runway into Q3 2027. Details of the structure or terms are contained in the referenced news release.
Cardiol Therapeutics Inc., a foreign private issuer based in Oakville, Ontario, furnished a Form 6-K indicating it files annual reports on Form 40-F. The report primarily submits a news release announcing Cardiol’s participation in a fireside chat at Canaccord Genuity’s 45th Annual Growth Conference.